Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
| (1) | Registration Statement (Form S-8 No. 333-269262) pertaining to the 2018 Equity Incentive Plan, the 2020 Equity Incentive Plan and the 2020 Employee Stock Purchase Plan of ARS Pharmaceuticals, Inc. (formerly Silverback Therapeutics, Inc.) |
| (2) | Registration Statement (Form S-8 No. 333-261980) pertaining to the 2020 Equity Incentive Plan and the 2020 Employee Stock Purchase Plan of ARS Pharmaceuticals, Inc. (formerly Silverback Therapeutics, Inc.) |
| (3) | Registration Statement (Form S-3 No. 333-261979) of ARS Pharmaceuticals, Inc. (formerly Silverback Therapeutics, Inc.) |
| (4) | Registration Statement (Form S-8 No. 333-254827) pertaining to the 2020 Equity Incentive Plan and the 2020 Employee Stock Purchase Plan of ARS Pharmaceuticals, Inc. (formerly Silverback Therapeutics, Inc.) |
| (5) | Registration Statement (Form S-8 No. 333-251143) pertaining to the 2016 Equity Incentive Plan, the 2020 Equity Incentive Plan and the 2020 Employee Stock Purchase Plan of ARS Pharmaceuticals, Inc. (formerly Silverback Therapeutics, Inc.) |
of our report dated March 23, 2023, with respect to the consolidated financial statements of ARS Pharmaceuticals, Inc. included in this Annual Report (Form 10-K) of ARS Pharmaceuticals, Inc. for the year ended December 31, 2022.
/s/ Ernst & Young LLP
San Diego, California
March 23, 2023
